Condition
Sporadic Amyotrophic Lateral Sclerosis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 2 (2)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01849770Phase 2CompletedPrimary
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
NCT02781454Phase 2CompletedPrimary
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
NCT02969759Early Phase 1UnknownPrimary
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Showing all 3 trials